• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cytheris announces publication of preclinical study

Cytheris announces publication of preclinical study

March 1, 2011
CenterWatch Staff

Cytheris, a clinical stage biopharmaceutical company focused on research and development of therapies for immune modulation, has announced publication of data showing IL-7 is able to overcome factors that thwart an effective immune response during chronic viremia in diseases such as HIV infection and viral hepatitis.

The results also suggest in reduced viral load established by current treatments for chronic viral diseases, IL-7 therapy might produce and expand specific T-cells and promote a broad and durable immune mediated antiviral response.

The study utilized the murine model of lymphocytic choriomeningitis virus (LCMV) infection, an in vivo system for studying protective cytotoxic T-lymphocyte (CTL) responses involving the variant clone-13. The model has a chronic infection and a high viral turnover in mice; it mimics the viral antigen seen levels in HIV, HCV and HBV. Clone-13 infection has been powerful to characterize the dysfunctional immune response associated with chronic viremia, and numerous parallels with HIV, HCV and HBV.  The study elucidates the molecular mechanisms in which IL-7 is able to overcome the immune inhibitory effects of massive viral load. 
    

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing